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DIAGNOSIS
Surgical excision/incision biopsy of a node or 
affected extra-nodal tissue is the method of choice for 
diagnosis. Core needle biopsies may be performed in 
patients in whom surgical biopsy is excessively risky. 
Diagnosis is not based exclusively on the analysis of 
fine-needle aspirate, although this technique, together 
with adequate phenotyping, can be sufficient to confirm 
relapse [1]. 
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ABSTRACT
Diffuse large B-cell lymphoma (DLBCL) accounts for approximately 30% 
of non-Hodgkin lymphoma (NHL) cases in adult series. DLBCL is characterized 
by marked clinical and biological heterogeneity, encompassing up to 16 distinct 
clinicopathological entities. While current treatments are effective in 60% to 70% 
of patients, those who are resistant to treatment continue to die from this disease. 
An expert panel performed a systematic review of all data on the diagnosis, 
prognosis, and treatment of DLBCL published in PubMed, EMBASE and MEDLINE up 
to December 2017. Recommendations were classified in accordance with the Grading 
of Recommendations Assessment Development and Evaluation (GRADE) framework, 
and the proposed recommendations incorporated into practical algorithms. Initial 
discussions between experts began in March 2016, and a final consensus was reached 
in November 2017. The final document was reviewed by all authors in February 2018 
and by the Scientific Committee of the Spanish Lymphoma Group GELTAMO.
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Diagnosis of DLBCL is based on morphological, 
immunohistochemical, cytogenetic, and molecular 
analyses. DLBCL is characterized by the expression of pan 
B markers such as CD20, paired box protein 5 (PAX5), 
octamer transcription factor 2 (OCT2), and CD79a, 
which are detectable by immunohistochemistry (IHC) or 
flow cytometry [1]. Some entities, such as plasmablastic 
lymphoma, primary effusion lymphoma, anaplastic 
lymphoma kinase (ALK)-positive large B-cell lymphoma, 
and human herpes virus-8 (HHV-8)-positive DLBCL- 
not otherwise specified (NOS) show reduced expression 
of markers of B-cell differentiation and upregulation of 
plasma-cell differentiation antigens. In these cases, analyses 
of CD138, CD38, Ki67, MYC, multiple myeloma-1 
(MUM1), ALK, HHV-8, and Epstein-Barr virus (EBV)-
encoded small RNAs (EBERs) are recommended [1]. 
At least 2 molecular subtypes of DLBCL-NOS have 
been identified by gene expression profiling: the germinal 
center B-cell-like (GCB) and the activated B-cell-like 
(ABC), which differ in their prognosis [2]. These subtypes 
can be classified using a variety of immunohistochemical 
algorithms, which range in accuracy from 85% to 93% with 
respect to the gold standard (gene expression profiling) 
[3, 4]. The Hans algorithm demonstrated prognostic value 
for progression-free survival (PFS), although making 
therapeutic decisions based on these result is not currently 
supported by available evidence. Double protein (DP) 
expression of MYC and BCL2 is found in 20% to 35% of 
cases [5–7]. These cases are associated with worse survival 
in retrospective series, regardless of subtype (GCB vs. 
ABC). While it is recommended to note double MYC/BCL2 
expression, there is insufficient evidence to suggest that 
an alternative therapeutic approach should be taken based 
on this parameter. CD30 expression is observed in 14% 
to 25% of cases, and is more common in certain entities, 
such as primary mediastinal large B cell lymphoma. It is 
recommended to report its expression at diagnosis [8, 9]. 
Studies have described cases characterized by 
concurrent rearrangements of MYC and BCL2 and/or 
BCL6 (double/triple hit: DH/TH) [5–7, 10]. These cases 
account for 3% to 14% of DLBCL and over 30% of cases 
formerly classified as B-cell lymphoma with features 
intermediate between DLBCL and Burkitt lymphoma. 
These cases are usually diagnosed in advanced stages 
with frequent involvement of the bone marrow and 
central nervous system (CNS), show a GCB phenotype 
and MYC protein overexpression in most instances, and 
have an adverse prognosis [11, 12]. Demonstration of 
MYC, BCL2 and BCL6 rearrangements can be done using 
FISH (fluorescent in situ hybridization) or conventional 
cytogenetic techniques. Cases with DLBCL morphology 
and DH/TH are now classified as High Grade B cell 
Lymphoma DH/TH, based on 2016 World Health 
Organization (WHO) classification update.
Summary and recommendations for DLBCL 
diagnosis (Figure 1) 
1. Excisional/incisional biopsy of the adenopathy or 
affected extranodal tissue is the method of choice for the 
diagnosis of DLBCL (Grade 1A). 
2. Diagnosis of DLBCL is based on the results of 
histopathological, immunohistochemical, and cytogenetic/
molecular studies. The combination of this information 
with clinical data allows classification according to the 
WHO (Grade 1A). 
3. In all cases of DLBCL-NOS it is recommended 
to classify according to GCB/non-GCB phenotype, using 
the Hans algorithm (Grade 2B). 
4. It is advisable to evaluate expression of MYC 
and BCL2 in DLBCL samples (Grade 2A). 
5. Rearrangements of MYC, BCL2, and/or BCL6 
can be demonstrated using conventional cytogenetic 
techniques (karyotype) and/or FISH; this is a requirement 
for the diagnosis of cases of high-grade B cell lymphoma 
with DH/TH (Grade 2A). 
6. It is recommended to establish the presence or 
absence of CD30 expression by IHC in DLBCL samples 
at diagnosis (Grade 2B). 
STAGING AND RISK ASSESSMENT
A complete clinical history, including Eastern 
Cooperative Oncology Group (ECOG) functional status 
and the presence of B symptoms, and a complete physical 
examination, with particular emphasis on identifying 
lymphadenopathy and visceromegaly, are required, 
in addition to the following analyses: blood count; 
biochemical analysis including lactate dehydrogenase 
(LDH), beta2 microglobulin, urate, liver and renal 
function; proteinogram; and serology for hepatitis 
B (HBs antigen, anti-HBc), hepatitis C, and human 
immunodeficiency virus (HIV). 
Fluorodeoxyglucose (FDG)-positron emission 
tomography (PET)/computed tomography (CT) is the test 
of choice for diagnosis of DLBCL extension, as it offers 
greater diagnostic accuracy than CT with contrast owing 
to its greater sensitivity for the detection of disease [13]. 
At present there is insufficient evidence to recommend 
the routine use of PET/CT with high-dose CT with 
intravenous contrast; the use of this procedure rarely 
results in changes to patient management and entails an 
increase in the radiation to which the patient is exposed. 
PET/CT is of limited value for the detection of CNS 
disease, and therefore magnetic resonance imaging (MRI) 
or cerebrospinal fluid (CSF) analysis is recommended 
in cases of suspected infiltration [13]. Staging by bone-
marrow biopsy can be avoided in cases in which PET/CT 
reveals focal infiltration [13].
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Measurement of ventricular ejection fraction is 
recommended in patients over 60 years of age and those 
with a history of cardiac disease.
The International Prognostic Index (IPI) is used in 
clinical practice to assess patient prognosis [14], with the 
limitation that it does not allow identification of very high-
risk patients who have undergone immunochemotherapy 
[15]. Further independent studies are required to validate 
the proposed greater effectiveness of newer indices, 
including the National Comprehensive Cancer Network 
(NCCN)-IPI and GELTAMO-IPI [16, 17]. The inclusion of 
biomarkers and genes implicated in the biology of DLBCL 
has not significantly improved the prognostic accuracy of 
the IPI [18, 19]. The presence of concurrent MYC plus 
BCL2 and/or BCL6 rearrangements (DH/TH) confers an 
adverse prognosis, and is associated with an estimated 
9-fold increase in the risk of mortality [11, 12, 20]. 
Summary and recommendations for DLBCL 
staging and risk assessments
1. PET/CT is the standard method for the staging 
of patients with DLBCL, both in clinical practice and in 
clinical trials (Grade 1B). 
2. Bone marrow biopsy can be avoided in cases in 
which PET/CT reveals bone infiltration (Grade 2C). 
3. The IPI is the standard prognostic index used in 
clinical practice. It is useful as a prognostic tool to stratify 
patients in clinical trials (Grade 1A). 
4. High grade B cell lymphoma with DH/TH (i.e. 
concurrent translocations of MYC and BCL2, and/or 
BCL6) has an adverse prognosis (Grade 2B). 
TREATMENT
First-line therapy 
First-line treatment can be stratified based on the 
extent of disease (limited stage or disseminated), the age 
of the patient, and their IPI score. 
Limited stage disease (Ann Arbor I-II)
In the pre-rituximab era, treatment with 3 cycles of 
CHOP (cyclophosphamide, doxorubicin, vincristine, and 
prednisone) followed by radiotherapy of the affected area 
was established as the standard treatment; this approach 
resulted in better PFS than 6 cycles of CHOP alone, 
although with longer follow-up no differences in OS were 
observed between patients who received radiotherapy 
and those who did not [21, 22]. In the rituximab era, 
 2 randomized trials have been performed. The Lymphoma 
Study Association (LYSA) group conducted a trial in 
which patients with non-bulky (<7 cm) limited-stage 
DLBCL were treated with 4 cycles of rituximab-CHOP 
(R-CHOP) and patients with high risk factors were treated 
with 2 additional cycles of R-CHOP. Those in complete 
metabolic remission (CMR) after 4 cycles of R-CHOP 
were randomized to 2 groups: involved-field radiation 
therapy (IFRT) or observation. No differences in event-
free survival (EFS) (89% vs. 92%) or overall survival 
(OS) (92% vs. 96%) were observed [23]. Those who did 
not achieve CMR after 4 cycles of R-CHOP underwent 
2 additional cycles of R-CHOP and IFRT. In the German 
UNFOLDER study, young patients with bulky limited-stage 
Figure 1: Histopathological diagnosis of DLBCL. Tissue biopsy. (‡) Other entities: [T cell/histiocyte-rich large B-cell lymphoma, 
primary CNS large B-cell lymphoma, primary “leg type” large B-cell lymphoma, EBV-positive large B-cell lymphoma-NOS, DLBCL 
associated with chronic inflammation, lymphomatoid granulomatosis, primary mediastinal large B-cell lymphoma (thymic), Intravascular 
large B-cell lymphoma, Burkitt-like lymphoma with 11q aberration, B-cell lymphoma, Unclassifiable, with features intermediate between 
Hodgkin´s lymphoma and DLBCL (grey zone B-cell lymphoma), large B-cell lymphoma with IRF4 rearrangement]. DLBCL: large B-cell 
lymphoma; NOS: Not otherwise specified.
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DLBCL were randomized to receive 6 cycles of R-CHOP 
followed by radiotherapy or not. The R-CHOP without 
radiotherapy arm was prematurely closed due to a high 
rate of relapse [24], and R-CHOP×6 + IFRT is therefore 
recommended for this group of patients.
Disseminated disease (Ann Arbor III-IV)
Patients aged 60–80 years
The standard treatment in these patients is 6 to 
8 cycles of R-CHOP every 21 days, based on the results of 
the French group trial that compared this treatment with 
CHOP without R and observed a significant increase in 
survival in the former group [25, 26]. Increasing dose 
density, which appeared to be beneficial in the RICOVER 
trial [14, 27], produced no benefits in 2 large randomized 
trials [28, 29]. Neither the addition of bortezomib to the 
R-CHOP-like regimen nor the substitution of rituximab 
with obinutuzumab (a type II anti-CD20 antibody) 
improved patient survival [30, 31]. Use of radiotherapy to 
treat extranodal lesions or bulky disease is controversial. 
However, its use is considered based on the findings of a 
cohort study in which patients that received radiotherapy 
had better progression-free survival (PFS) [32]. 
Low or low-intermediate risk patients (IPI score, 
0–2) aged <60 years 
The standard treatment in these patients is 6 to 8 
cycles of R-CHOP every 21 days, based on the results of the 
MiNT trial, which compared R-CHOP-like with CHOP-like 
regimens and found clear improvements in PFS and OS in 
patients in whom R was added [33, 34]. Patients in this trial 
with bulky disease received radiotherapy. A French trial of 
young patients with DLBCL and an age-adjusted (aa)-IPI = 1 
compared the most intensive R-ACVBP (rituximab-
doxorubicin, cyclophosphamide, vindesine, bleomycin 
and prednisone)/methotrexate (MTX)/R-ICE (rituximab-
ifosfamide, carboplatin, and etoposide) followed by 
autologous-hematopoietic stem cell transplantation (auto-
HSCT) regimen with R-CHOP, without using radiotherapy 
in any arm, and observed an increase in survival in 
patients treated with the intensive regimen, which was also 
associated with greater toxicity [35, 36]. 
High-risk patients (IPI score, 3–5) aged <60 years 
While there is no standard treatment for this 
group of patients, they are usually treated with 6 to 8 
cycles of R-CHOP every 21 days. Dense-dose R-CHOP 
has shown no benefits [28]. In a phase II study, high-
risk patients (IPI: 3–5; aaIPI: 2–3) were treated with 
DA-EPOCH-R [dose-adjusted-(etoposide, prednisone, 
vincristine, cyclophosphamide, doxorubicin-rituximab)] 
 [37], and a randomized study (NCT00118209) comparing 
DA-EPOCH-R with R-CHOP is currently underway 
[38]. Some studies have investigated the use of high-dose 
chemotherapy followed by transplantation of autologous 
hematopoietic stem cells [39], but have reported 
contradictory results, and therefore this treatment cannot 
be recommended for all patients.
Patients with comorbidities or aged >80 years
There is no standard treatment for patients of over 
80 years of age. A geriatric assessment is recommended 
to identify “fit” patients. The combination of rituximab 
and polychemotherapy with doxorubicin induces 
complete remission and prolongs survival. Therefore, it 
is recommended to use conventional treatments such as 
R-CHOP, or an attenuated immunochemotherapy regimen 
(R-miniCHOP) [40]. In patients with cardiac pathologies 
adriamycin can be omitted (R-COP) or substituted 
with liposomal doxorubicin or other agents such as 
mitoxantrone, etoposide, or gemcitabine [41–43]. 
Summary and recommendations for DLBCL 
first-line therapy (Figure 2)
1. R-CHOP × 4 cycles is recommended for patients 
with localized DLBCL without adverse prognostic 
factors (Grade 1A). For patients with high risk factors 
in CR by PET/CT, 2 additional courses of R-CHOP are 
recommended (Grade 1A). If PET/CT CR is not achieved, 
the recommendation is to give 2 additional cycles of 
R-CHOP and IFRT (Grade 1A). 
2. R-CHOP × 6 cycles plus radiotherapy of the 
bulky area is recommended for patients with localized 
bulky DLBCL (>7 cm) (Grade 2B). 
3. The standard treatment for patients with 
disseminated DLBCL aged 60 to 80 years is 6–8 cycles 
of R-CHOP administered every 21 days (Grade 1A). 
Radiotherapy for bulky disease or extranodal lesions may 
be of benefit in some patients (Grade 1B). 
4. The standard treatment for patients with 
disseminated DLBCL aged less than 60 years with an IPI 
of 0–2 is 6 cycles of R-CHOP administered every 21 days 
(Grade 1A). Radiotherapy for bulky disease or extranodal 
lesions may be of benefit in some patients (Grade 1B). 
5. There is no standard treatment for patients with 
disseminated DLBCL aged less than 60 years with a high 
IPI (IPI:3–5); these patients should be included in clinical 
trials. They are generally treated with 6 or 8 cycles of 
R-CHOP administered every 21 days (Grade 1B). 
6. There is no standard treatment for patients with 
disseminated DLBCL aged over 80 years. It is recommended 
to use conventional treatments such as R-CHOP whenever 
possible, or to use attenuated doses of the same drugs 
(R-miniCHOP) (Grade 1C). Doxorubicin can be replaced 
with liposomal doxorubicin or other agents such as 
etoposide, mitoxantrone, or gemcitabine (Grade 1C). 
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Salvage therapy
About 30-40% of patients have refractory disease 
or relapses after receiving first-line treatment. It is 
recommended whenever possible to repeat the biopsy 
of the tumor tissue to identify false-positive PET/CT or 
exclude other pathologies [13]. 
High-dose chemotherapy
Salvage immunochemotherapy is the treatment 
of choice in young patients (<60–70 years) without 
comorbidities. In chemosensitive patients, the response 
should be consolidated with high-dose chemotherapy 
and auto-HSCT. The superiority of auto-HSCT over 
consolidation chemotherapy was established in the 
international randomized PARMA study in the 1990s [44]. 
No such studies have been performed in the rituximab era. 
No specific salvage regimen has demonstrated superiority 
over others. In the international CORAL study, R-DHAP 
(rituximab-dexamethasone, cytosine arabinoside, and 
cisplatin) and R-ICE (rituximab-ifosfamide, carboplatin, 
etoposide) showed similar efficacy, but the former was 
associated with greater renal toxicity and thrombopenia 
[45]. In the randomized NCIC-CTG LY.12 international 
trial, in which patients received R-GDP (rituximab-
gemcitabine, cisplatin, and dexamethasone) or R-DHAP, 
both regimens showed similar efficacy, but R-DHAP 
resulted in greater toxicity (febrile neutropenia and 
thrombopenia) [46]. However results are very poor with 
any of the aforementioned regimens, with PFS around 
20% [47]. Therefore, the best option for these patients is 
to enroll them in clinical trials of regimens that include 
new drugs. In this context, the substitution of rituximab 
with ofatumumab showed no benefit in a randomized 
study [48]. 
The main prognostic factor at the time of 
transplantation is lymphoma status, as determined by 
PET/CT, since patients with CMR have significantly 
better survival than patients in partial remission (PR) 
(PFS: 72%–87% vs. 18%–49%) [49, 50]. There are no 
randomized studies demonstrating the superiority of any 
conditioning regimen. The BEAM (BCNU, etoposide, 
cytarabine and melphalan) regimen is the most widely 
used in Europe. The incorporation of radioimmunotherapy 
into the conditioning regimen showed no superiority in 
the only phase III clinical trial published to date [51]. 
Maintenance rituximab after auto-HSCT also showed no 
benefits in the CORAL study [52]. Several retrospective 
studies have reported that allogeneic hematopoietic stem 
cell transplantation (allo-HSCT) may be effective in 
patients with relapse or progression after multiple lines 
Figure 2: First line therapy. *Risk factors: High LDH level, Ann Arbor stage II, ECOG PS > 0, Age > 60 years. DLBCL: large 
B cell lymphoma; IFRT: involved-field radiation therapy; IPI: international prognostic index; R-CHOP: rituximab, cyclophosphamide, 
daunorubicin (doxorubicin), vincristine, prednisone; R-COMP: rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; 
RCOP: rituximab, cyclophosphamide, vincristine, prednisone.
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of treatment, including auto-HSCT [53–55]. Given that 
myeloablative regimens are associated with a very high 
non-relapse-related mortality rate (40%–50%), it seems 
advisable to use non-myeloablative regimens (mortality: 
20%–30%; PFS: 20%–40%). The status of the lymphoma 
is the most important prognostic factor, with very poor 
results in patients with chemorefractory disease [53–55]. 
In high-risk patients in PR after salvage therapy, allo-
HSCT may be an alternative to auto-HSCT [56]. In 
controlled studies, allo-HSCT could be also an alternative 
to auto-HSCT [57, 58], for patients with very high-risk 
features, such as primary refractory disease. 
Non-auto-HSCT candidates 
Evidence supporting the efficacy of salvage 
regimens in these patients is based on phase II studies. 
There is no standard regimen established and durable 
remissions are uncommon. 
R-GemOx (rituximab-gemcitabine, oxaliplatin) 
results in overall response rates (ORR) of about 60% 
with a 1-year OS rate of 45% and a PFS of around 
25% at 12 months [59, 60]. While results obtained with 
R-bendamustine (rituximab-bendamustine) in phase II 
trials vary significantly, this regimen has an acceptable 
toxicity profile and is relatively efficacious (ORR > 30%) 
in frail patients [61]. However, whenever possible these 
patients should be enrolled in clinical trials.
Third-line and later lines of therapy
Third-line therapy is an option in patients who 
do not respond to salvage treatment. The scientific 
evidence supporting the efficacy of third-line therapy is 
lower than that published for previous lines of therapy. 
In some cases patients may be treated with second-line 
polychemotherapy regimens not used previously. A 
study comparing pixantrone monotherapy with other 
chemotherapeutic agents in monotherapy in relapsed 
patients that previously received a median of 3 lines 
of therapy reported overall response rates of 40% 
for pixantrone versus 14.3% for the comparator arm 
[62]. Lenalidomide in monotherapy or combined with 
rituximab shows efficacy in this situation, producing an 
overall response rate of around 30%, with a relatively 
short-duration response [63, 64]. Despite the higher 
ORR observed for the non-GCB subtype, no differences 
in PFS or OS were detected between the GCB and non-
GCB subtypes [65]. There are no clinical trial data to 
indicate which other drugs in monotherapy (gemcitabine, 
oxaliplatin, etoposide, mitoxantrone, vinorelbine) are 
most appropriate in each case. These treatments have 
been used in comparator arms in several phase II clinical 
trials, and have shown poor efficacy in terms of ORR 
(usually <20%), but some clinical benefits [62]. Efficacy 
data are available for 2 treatment regimens at metronomic 
doses: celecoxib, methotrexate, and cyclophosphamide, 
which produced an ORR of 30% [66], and the PEP-C 
(prednisone, etoposide, procarbazine- cyclophosphamide) 
regimen, which produced a response in 3 out of 9 patients 
with DLBCL, with high toxicity [67]. Inclusion of these 
patients in clinical trials is recommended wherever 
possible.
Summary and recommendations for DLBCL 
salvage therapy (Figure 3)
1. In refractory disease or relapse, it is advisable to 
repeat the tumor biopsy before proceeding to second-line 
treatment (Grade 1B). 
2. The salvage regimen with the most favorable 
toxicity profile is R-GDP, although other regimens such 
as R-ESHAP, R-DHAP, and RICE have shown similar 
efficacy (Grade 1B). Patients who achieve at least PR 
following salvage therapy should undergo auto-HSCT 
with BEAM or similar conditioning regimen (Grade 1B). 
3. Allogeneic transplantation is an option in patients 
that relapse after auto-HSCT (Grade 1C). 
4. In patients with refractory or relapsing DLBCL 
who are not candidates for auto-HSCT, moderate-to-low 
intensity regimens using R-GemOx or R-bendamustine are 
recommended (Grade 1B). 
5. There are no specific recommendations for third 
or later lines of therapy. Pixantrone has demonstrated 
superiority over other drugs in monotherapy in relapsed 
patients (Grade 1B). 
RESPONSE EVALUATION AND 
FOLLOW-UP
PET/CT at the end of treatment is the best instrument 
for assessing the patient’s response. It is recommended 
to apply the criteria of the Lugano classification system, 
using the Deauville 5-point scale. The presence of a 
residual mass in the context of CMR is not a criterion for 
active disease. In cases of metabolically active residual 
disease, it is advisable to perform a biopsy if salvage 
therapy is considered [13, 68]. 
Interim PET (iPET)/CT is used to assess the 
early response, but there are some problems due to 
standardization regarding the technique itself and its 
interpretation [13]. CMR on iPET carries an excellent 
prognosis. Studies evaluating intensification treatment 
based on iPET have shown no benefit over R-CHOP 
[69, 70]. Therefore, iPET is not recommended as a basis 
for altering treatment outside of clinical trials. 
After achieving CMR, clinical follow-up, with 
clinical history, physical examination, and laboratory 
work-up, should be performed every 3 to 4 months for 
the first 2 years and every 6 months for the following 
3 years [13]. This should be followed by annual clinical 
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follow-up to assess potential late toxicity and the possible 
development of second neoplasms. There is no evidence 
to suggest that routine CT or PET/CT provides any 
advantage over clinical follow-up assessment [13]. Most 
relapses occur outside of planned follow-up visits and only 
1%–2% are detected in imaging tests [71], which provide 
no advantages for early detection of relapse and have no 
impact on survival. 
Summary and recommendations for DLBCL 
response evaluation and follow-up
1. PET/CT is the standard imaging modality used to 
assess the response at the end of treatment (Grade 1A). 
2. Evaluation of the response should be carried out 
visually using the Deauville scale (Grade 2B). 
3. In cases of metabolically active residual disease, 
it is advisable to perform a biopsy if salvage therapy is 
considered (Grade 2C).
4. In clinical practice, iPET is not recommended 
as a basis for changing treatment, unless there is clear 
evidence of progression, and should be reserved for 
clinical trials (Grade 2C). 
5. The routine use of imaging tests in the follow-
up of patients with DLBCL in complete remission is 
discouraged (Grade 1A). 
SPECIAL SITUATIONS
CNS prophylaxis 
This topic has been extensively discussed in recent 
specific guidelines published by the GELTAMO group 
[72]. 
Tumor lysis syndrome prophylaxis 
Risk factors for tumor lysis syndrome (TLS) include 
bulky tumor burden, a high proliferative index, pre-
existing renal failure, advanced age, and treatment with 
highly active cell-cycle-specific agents. Prophylaxis with 
allopurinol is recommended in patients at intermediate risk 
of TLS. Treatment should be maintained for up to 7 days 
[73]. In high-risk patients (bulky disease [≥10 cm], LDH 
over twice the upper limit of normal, patients in the “MYC-
driven” subgroup, and patients with renal impairment) 
Figure 3: Salvage therapy. BEAM: carmustine, etoposide, cytarabine, melphalan; HSCT: hematopoietic stem cell transplantation; 
R-DHAP: rituximab, dexamethasone, cytarabine, cisplatin; R-ESHAP: rituximab, etoposide, methylprednisolone; cytarabine; cisplatin; 
R-GDP: rituximab, gemcitabine, cisplatin, dexamethasone; R-ICE: rituximab, ifosfamide, carboplatin, etoposide.
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[73, 74], TLS prophylaxis with hydration and rasburicase 
is recommended [75]. The volume infused is not specified, 
but 3 L/24 hours in adults seems a reasonable estimate. 
The standard dose of rasburicase is 0.2 mg/kg, for 
5–7 days. However, studies have reported the use of lower 
doses, such as 0.1 mg/kg/day or 0.15 mg/kg/day, with 
a treatment duration adjusted to the patient’s evolution, 
and the majority of patients only required a single dose 
[74, 76]. Concomitant use of rasburicase and allopurinol is 
not recommended, since the latter can reduce the efficacy 
of rasburicase.
Summary and recommendations for DLBCL 
TLS prophylaxis
1. Patients with low risk TLS should be managed 
by monitoring water balance and laboratory parameters, 
and only the administration of allopurinol should be 
considered (Grade 2C). Intermediate-risk patients 
should be treated with allopurinol (7 days) and hydration 
(Grade 2C). High-risk patients should be treated with 
rasburicase and hyperhydration (Grade 1B). 
SPECIAL SUBTYPES
Plasmablastic lymphoma
Plasmablastic lymphoma is mainly associated with 
human immunodeficiency virus (HIV) infection, but it 
has also been described in patients with other types of 
immune compromise and in immunocompetent patients 
[77, 78]. It usually presents with extranodal involvement, 
affecting the oral cavity in almost half of all cases. The 
prognosis is poor, with median survival ranging from 
8–15 months [78]. There is no standard treatment. Some 
reviews recommend more intensive chemotherapy 
regimens such as EPOCH (etoposide, doxorubicin, and 
cyclophosphamide with vincristine and prednisone) or 
hyper CVAD/MA (hyperfractionated cyclophosphamide, 
vincristine, doxorubicin, and dexamethasone alternating 
with methotrexate and cytarabine), especially given 
the role of MYC alterations in the pathogenesis of this 
lymphoma [77]. However, 2 retrospective studies found 
no survival benefit of intensive regimens over CHOP in 
HIV patients [79, 80]. The use of CNS prophylaxis has not 
been systematically evaluated, but seems advisable given 
the frequent extranodal involvement, the high proliferative 
index, and the presence of MYC rearrangements in many 
cases [77]. Loco-regional radiotherapy has been used in 
some cases, although its role has not been fully established 
[77]. The use of auto-HSCT remains controversial: while 
some authors have proposed it as first-line consolidation 
therapy [81], others propose that it should only be used in 
cases that fulfill risk criteria [82, 83]. The incorporation 
of new drugs has produced promising results in recent 
studies. These include thalidomide, lenalidomide, and in 
particular the proteasome inhibitor bortezomib, which 
when combined with DA-EPOCH [84] or with CHOP [85] 
followed by auto-HSCT produced long-term remission.
Primary mediastinal B-cell lymphoma  
(PMBCL) 
This predominantly affects young adults (mainly 
women aged 30–40 years) and usually manifests as a bulky 
mediastinal mass, often with pleural or pericardial effusion 
and superior vena cava syndrome [86, 87]. Although there 
are few prospective studies, some sub-analyses such as 
the MinT trial [88] (with 11% of patients with PMBCL) 
concluded that the addition of rituximab to CHOP-like 
(CHOP or CHOEP) regimens significantly increased 
the CR rate and increased 3-year PFS (78% vs. 52%, 
 p = 0.01) but not OS (88.5% vs. 78.2%, p = 0.15), possibly 
due to the small number of patients in this subgroup. 
Other retrospective studies have compared R-CHOP with 
CHOP regimens, and found that the former provides better 
outcomes [89]. A prospective phase II NCI study in which 
patients received infusional DA-EPOCH-R reported a CR 
rate of 94%, a 5-year EFS of 93%, and an OS of 97%. 
Only 2 patients required radiotherapy [86]. However, to 
date, no prospective study has directly compared DA-
EPOCH-R with R-CHOP. 
The role of radiotherapy is controversial. In a series 
that included patients treated with R-CHOP, CHOP, and 
intensive regimens such as MACOP-B (methotrexate, 
doxorubicin, cyclophosphamide, vincristine, prednisone, 
and bleomycin) and VACOP-B (etoposide, doxorubicin, 
cyclophosphamide, vincristine, prednisone, and 
bleomycin), the addition of radiotherapy had no effect 
on PFS or OS [90]. The use of DA-EPOCH-R provides 
good results without the need for radiotherapy [86]. The 
definitive role of radiotherapy may be clarified upon 
publication of the results of the International Extranodal 
Lymphoma Study Group (IELSG-37) study, in which 
patients who achieve CMR are randomized to radiotherapy 
or observation arms (https://www.clinicaltrials.gov/; 
NCT01599559). Frontline consolidation treatment 
with auto-HSCT does not provide any benefit [91]. 
Refractoriness and relapse are usually associated with an 
unfavorable prognosis [92]. Treatment is usually based 
on salvage immunochemotherapy and consolidation with 
auto-HSCT, and the results obtained tend to be poorer than 
those observed for DLBCL-NOS [93]. 
High-grade lymphoma with MYC and BCL2 and/
or BCL6 rearrangement (double/triple hit)
This type of lymphoma usually presents at advanced 
age, with high LDH and extranodal involvement, especially 
CNS infiltration [94]. It is important to differentiate DH/
TH lymphomas from those with DP expression of MYC 
and BCL2. In patients with DH/TH lymphomas, standard 
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treatment based on R-CHOP offers poor results with a CR 
rate of 40% and OS at 2 years of 35%–40% [5, 20, 95, 
96]. Most intensive chemotherapy regimens, in particular 
DA-EPOCH-R, appear to achieve better CR and PFS than 
R-CHOP [5, 20, 97]. However, in a meta-analysis [98] of 
11 studies and a total of 394 patients treated with R-CHOP 
(n = 180), R-EPOCH (n = 91), and R-hyper CVAD/R-MA 
or R-CODOX-M/R-IVAC (rituximab-cyclophosphamide, 
doxorubicin, vincristine, methotrexate/ifosfamide, 
etoposide, high-dose cytarabine) (n = 123), the risk of 
progression was significantly lower in R-EPOCH- versus 
R-CHOP-treated patients, but no significant differences in 
OS were observed between the 3 regimens, with median 
OS ranging from 20–30 months. Retrospective studies 
have corroborated the poor results obtained with auto-
HSCT in patients with DH lymphoma [99]. Inclusion 
of these patients in clinical trials is recommended. CNS 
prophylaxis is highly recommended as it appears to be 
associated with improved survival [100]. 
DLBCL in HIV patients
DLBCL is an AIDS-defining neoplasm. The 
prognosis of patients with DLBCL before the antiretroviral 
(ART) era was poor, but since the introduction of 
highly active ART (HAART), survival is similar to 
that of non-HIV-infected patients, using the same 
immunochemotherapy regimens [101, 102]. In these 
patients adequate antimicrobial prophylaxis and the use of 
G-CSF as primary prophylaxis for febrile neutropenia is 
recommended. Some studies suggested a higher incidence 
of CNS infiltration in the pre-ART era [103], but with 
HAART there has been a decrease in CNS infiltration, 
and therefore the recommendations for prophylaxis of 
CNS involvement are the same as for immunocompetent 
patients. 
Post-transplant lymphoproliferative disorder 
Post-transplant lymphoproliferative disorder 
(PTLD) is one of the most serious complications that can 
affect patients undergoing solid-organ transplantation or 
allogeneic stem cell transplantation. Incidence ranges 
from 1%–20%. As a result of the immunodepressive 
state induced to prevent rejection, T lymphocytes fail 
to adequately control the proliferation of EBV-infected 
B lymphocytes, increasing the likelihood of errors 
during gene rearrangement, activation of oncogenes, 
inactivation of suppressor genes, and the development of 
lymphoma. The WHO classification of PTLD describes 
3 types: early lesions which are usually polyclonal; 
polymorphic PTLD; and monomorphic PTLD, which 
Figure 4: Treatment for special DLBCL subtypes. CNS: central nervous system; DA-EPOCH-R: dose-adjusted, etoposide, 
prednisone, vincristine, cyclophosphamide, daunorubicin (doxorubicin), rituximab; EBV: Epstein-Barr virus; G-CSF: granulocyte 
colony stimulating factor; PTLD: post-transplant lymphoproliferative disorder; R-CHOP: rituximab, cyclophosphamide, daunorubicin 
(doxorubicin), vincristine, prednisone.
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is characterized by conventional-like lymphomas and is 
usually monoclonal. Most cases of monomorphic PTLD 
are large B-cell lymphomas. Around a half of all cases 
appear within 1 year of transplantation. Late-onset cases 
appear similar to conventional lymphoma, although 
they are more frequently characterized by extranodal, 
especially gastrointestinal, involvement. PTLD is staged 
by PET/CT [13, 68]. In cases of suspected PTLD, the first 
step is to reduce immunosuppression without endangering 
the viability of the graft [104]. This achieves a response 
rate of 20%–50%, particularly in cases of polymorphic 
PTLD. Localized PTLD can be eradicated by surgical 
resection or radiotherapy. In cases of disseminated 
PTLD with CD20 expression, rituximab monotherapy 
is the treatment of choice, with CR rates of 60%–70% 
[105, 106]. If CR is not achieved, a short course of 
3–4 cycles of immunochemotherapy (e.g. R-CHOP) 
is recommended. Patients who fail to respond to other 
therapies have been treated with infusions of specific 
allogeneic cytotoxic T lymphocytes against EBV, 
resulting in a CR rate of 45% [107, 108]. This strategy 
cannot be applied in all centers due to the high associated 
costs and the specialized equipment required. In cases of 
transplant recipients at high risk of PTLD (e.g. recipients 
of haploidentical hematopoietic stem cell transplants, 
recipients of multivisceral and heart/lung transplants, and 
patients who are EBV-negative before transplantation) 
EBV copy number needs to be monitored frequently during 
the first 6 months to initiate pre-emptive therapy (1–4 
doses of weekly rituximab, depending on the evolution of 
the viral load) while reducing immunosuppression [109]. 
There is no standard threshold for treatment initiation. 
Some authors recommend treatment if copy number 
exceeds 1000, while others propose thresholds of 10,000 
or even 40,000. 
Summary and recommendations for special 
DLBCL subtypes (Figure 4)
1. There is no standard treatment for plasmablastic 
lymphoma. DA-EPOCH is recommended especially in 
cases with MYC rearrangement (Grade 2C). 
2. In patients with primary mediastinal lymphoma, 
treatment is based on immunochemotherapy with 
rituximab (Grade 1A). More intensive regimens such as 
DA-EPOCH-R may be more effective, particularly in 
cases with unfavorable risk factors (Grade 2B). The effect 
of complementary radiotherapy in patients who have 
not achieved CMR is unclear. Whenever possible, it is 
recommended to repeat the biopsy given the high rate of 
false positives and the limited value of PET/CT in these 
cases (Grade 1B).
3. There is no standard therapy for DH/TH 
lymphomas; these patients should be included in clinical 
trials. Immunochemotherapy using intensive regimens 
(e.g. DA-EPOCH-R) or others, such as those used in 
Burkitt lymphoma, are recommended (Grade 1B). No 
data have demonstrated a benefit of auto-HSCT as first-
line consolidation therapy in patients with CR (Grade 2C). 
CNS prophylaxis is recommended (Grade 1C).
4. In HIV patients, the treatment of DLBCL is 
based on immunochemotherapy, preferably with standard 
R-CHOP (Grade 2B). Multidisciplinary management 
is recommended to determine the optimal antiretroviral 
treatment regimen (Grade 2B). Primary prophylaxis with 
G-CSF is recommended (Grade 2B). In patients with 
chemosensitive relapse, the same salvage treatments as 
those used in immunocompetent patients are recommended, 
followed by consolidation with auto-HSCT (Grade 1B). 
5. In PTLD patients, the first recommendation is 
to reduce immunosuppression (Grade 1B), followed, in 
CD20-positive cases, by weekly rituximab treatment (4–8 
doses). If CR is not achieved patients may require 3–4 
cycles of R-CHOP (Grade 1B). In transplant patients with 
a high risk of PTLD, monitor EBV copy number during 
the first 6 months, and institute pre-emptive therapy if 
copy number increases, reducing immunosuppression and 
administering 1–4 weekly doses of rituximab, depending 
on the evolution of the viral load (Grade 1C).
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